Metastatic Colorectal Cancer Treatment by Mutation Status
All patients with metastatic colorectal cancer require comprehensive molecular testing including RAS (KRAS/NRAS), BRAF V600E, MSI/MMR status, HER2 amplification, and NTRK/RET fusions, with next-generation sequencing being the preferred testing method. 1
Essential Biomarker Testing
Testing should be performed upfront on all metastatic colorectal cancer patients using NGS panels, which can identify both common and rare actionable alterations 1. The following biomarkers dictate treatment selection:
- RAS (KRAS/NRAS) mutations - exons 2,3, and 4
- BRAF V600E mutation
- MSI-H/dMMR status
- HER2 amplification
- NTRK gene fusions
- RET fusions
Treatment by Mutation Status
MSI-H/dMMR Tumors (5-10% of cases)
For MSI-H/dMMR metastatic colorectal cancer, pembrolizumab monotherapy is the standard of care in first-line treatment, demonstrating superior outcomes compared to chemotherapy plus targeted agents. 2
- First-line: Pembrolizumab (anti-PD-1 monotherapy) is recommended as standard of care [Level I, A evidence; ESMO-MCBS score: 4] 2
- After chemotherapy progression: Ipilimumab-nivolumab combination [Level III, B evidence; ESMO-MCBS score: 3] 2
- These patients show limited response to conventional chemotherapy but high susceptibility to immune checkpoint inhibition 3
- Important caveat: 10-30% exhibit primary resistance to immunotherapy 4
RAS Wild-Type Tumors (50% of cases)
Treatment selection depends critically on tumor sidedness:
Left-Sided, RAS Wild-Type Tumors
Doublet chemotherapy (FOLFOX or FOLFIRI) plus anti-EGFR monoclonal antibodies (cetuximab or panitumumab) is the preferred first-line option for left-sided, RAS wild-type tumors. 2
- Anti-EGFR therapy extends median survival by 2-4 months compared to chemotherapy alone 5
- Options: FOLFOX + panitumumab [ESMO-MCBS score: 4] or FOLFIRI + cetuximab [ESMO-MCBS score: 4] 2
- Critical restriction: Never use anti-EGFR antibodies with capecitabine or bolus 5-FU due to increased toxicity without efficacy 2
Right-Sided, RAS Wild-Type Tumors
Chemotherapy plus bevacizumab is preferred for right-sided, RAS wild-type tumors. 2
- Anti-EGFR antibodies show reduced efficacy in right-sided primaries
- Exception: When high response rates are needed for conversion surgery, anti-EGFR therapy may be considered 2
RAS-Mutant Tumors (40% of cases)
Patients with KRAS or NRAS mutations should never receive cetuximab or panitumumab as these tumors are essentially insensitive to EGFR inhibition. 1
- Standard treatment: Chemotherapy doublet (FOLFOX, FOLFIRI, or CAPOX) plus bevacizumab
- FOLFOXIRI triplet plus bevacizumab for fit patients without comorbidities [ESMO-MCBS score: 2] 2
- Exception: KRAS G12C-specific mutations (17% of KRAS-mutant cases) can receive cetuximab/panitumumab when combined with sotorasib or adagrasib 1
Important restriction: Never combine anti-VEGF with anti-EGFR antibodies 2
BRAF V600E-Mutant Tumors (5-10% of cases)
For BRAF V600E-mutant metastatic colorectal cancer, encorafenib plus cetuximab is the recommended targeted therapy, preferably in second or third line. 2
- Encorafenib-cetuximab extends overall survival to 9.3 months versus 5.9 months with standard chemotherapy 5
- Recommended as best option in second-line [Level I, A evidence; ESMO-MCBS score: 4; ESCAT: I-A] 2
- Also recommended in third-line if not used earlier 2
- First-line consideration: FOLFOXIRI plus bevacizumab for right-sided BRAF-mutant tumors when downstaging is needed 2
HER2-Amplified Tumors (3-5% of cases)
In HER2-positive metastatic colorectal cancer, HER2 dual blockade therapy is recommended, particularly in RAS wild-type tumors. 2
- Recommended in third-line and beyond [Level III, C evidence; ESCAT: II-B] 2
- Especially effective in RAS wild-type tumors
- HER2 amplification testing should be performed on all metastatic cases 1
NTRK Fusion-Positive Tumors (<1% overall, but 5.3% in dMMR/MSI)
NTRK gene fusions, though rare, are actionable with TRK inhibitors (larotrectinib, entrectinib) and should be tested via NGS panels. 1
- Critical finding: NTRK fusions occur in 5.3% of dMMR/MSI metastatic colorectal cancer, particularly in sporadic cases with MLH1 promoter hypermethylation and RAS/BRAF wild-type status 6
- TRK inhibitors show complete responses even after immunotherapy failure in MSI-H patients 6
- Testing caveat: Pan-TRK immunohistochemistry misses cases; FISH or NGS confirmation required 6
Second-Line Treatment Algorithms
After Oxaliplatin-Based First-Line
- Switch to irinotecan-based regimen (FOLFIRI) 2
- Add antiangiogenic (bevacizumab, aflibercept, or ramucirumab) regardless of prior bevacizumab use 2
- For RAS wild-type left-sided tumors not previously exposed to anti-EGFR: FOLFIRI + cetuximab/panitumumab 2
After Irinotecan-Based First-Line
Third-Line and Beyond
Options include:
- Regorafenib [Level I, A; ESMO-MCBS score: 1] 2
- Trifluridine-tipiracil [Level I, A; ESMO-MCBS score: 3] 2
- Anti-EGFR rechallenge in RAS wild-type patients who maintain wild-type status 2
- Encorafenib-cetuximab for BRAF V600E if not used earlier 2
Critical Pitfalls to Avoid
Never use anti-EGFR therapy in RAS-mutant tumors (except KRAS G12C with specific inhibitors) - these patients have virtually no chance of benefit and face unnecessary toxicity 1
Never combine anti-VEGF with anti-EGFR antibodies - not recommended due to lack of benefit 2
Never use FOLFOXIRI in patients >75 years, PS2, or significant comorbidities 2
Do not repeat molecular testing after standard cytotoxic chemotherapy - significant molecular changes are rarely observed 1
Confirm MSI-H/dMMR status if early progression on immunotherapy occurs - rule out pseudo-progression and verify testing accuracy 4
Repeat Testing Considerations
Repeat molecular testing should be considered after targeted therapy (not chemotherapy) to assess for acquired resistance mutations that may guide subsequent treatment decisions. 1